Prometheus Biosciences Inc (RXDX) PT Raised to $111 at RBC Capital, 'Strength of the PRA023 Topline Data Stands Alone'
Tweet Send to a Friend
RBC Capital analyst Gregory Renza raised the price target on Prometheus Biosciences Inc (NASDAQ: RXDX) to $111.00 (from $66.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
